Associated Genetic Biomarkers
CD28 is altered in 0.17% of all cancers with acute myeloid leukemia with t(6;9) (p23;q34.1); DEK-NUP214, peripheral T-cell lymphoma, not otherwise specified, acute myeloid leukemia, Burkitt lymphoma, and sezary syndrome having the greatest prevalence of alterations .
The most common alterations in CD28 are CD28 Mutation (0.09%), CD28 Amplification (0.07%), CD28 K81E (0.05%), CD28 A31V (0.02%), and CD28 Q25L (0.02%) .
CD28 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CD28 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CD28 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is CD28 Expression .
Abatacept, dexamethasone, and ixazomib are the most frequent therapies in trials with CD28 as an inclusion criteria .
Significance of CD28 in Diseases
Multiple Myeloma +
CD28 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CD28 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.